High-dose radiotherapy with or without androgen-deprivation therapy for intermediate-risk prostate cancer: Cancer control and toxicity

被引：0
|
作者：
Edelman, S.
Rossi, P. J.
Cooper, S.
Jani, A. B.
机构：
[1] Emory Univ, Atlanta, GA 30322 USA
[2] Atlanta VA Med Ctr, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 07期
关键词：
D O I：
10.1200/jco.2011.29.7_suppl.67
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
67
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
    Cagney, Daniel N.
    Dunne, Mary
    O'Shea, Carmel
    Finn, Marie
    Noone, Emma
    Sheehan, Martina
    McDonagh, Lesley
    O'Sullivan, Lydia
    Thirion, Pierre
    Armstrong, John
    BMC UROLOGY, 2017, 17
  • [42] Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
    Daniel N. Cagney
    Mary Dunne
    Carmel O’Shea
    Marie Finn
    Emma Noone
    Martina Sheehan
    Lesley McDonagh
    Lydia O’Sullivan
    Pierre Thirion
    John Armstrong
    BMC Urology, 17
  • [43] Androgen Deprivation Therapy and Radiotherapy Practice Patterns for Unfavorable Intermediate Risk Prostate Cancer
    Hasan, Shaakir
    Lazarev, Stanislav
    Garg, Madhur
    Mehta, Keyur
    Press, Robert
    Chhabra, Arpit
    Choi, J. Isabelle
    Simone, Charles
    Gorovets, Daniel
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (10): : S63 - S63
  • [44] Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate and high risk prostate cancer
    Krauss, D. J.
    Kestin, L. L.
    Brabbins, D. S.
    Gustafson, G. S.
    Chen, P. Y.
    Ghilezan, M. I.
    Vicini, F. A.
    Martinez, A. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S298 - S298
  • [45] Androgen-deprivation Therapy and Risk for Biliary Disease in Men with Prostate Cancer
    Saylor, Philip J.
    Smith, Matthew R.
    O'Malley, A. James
    Keating, Nancy L.
    EUROPEAN UROLOGY, 2014, 65 (03) : 642 - 649
  • [46] Is Neoadjuvant Androgen Deprivation Therapy Necessary for Patients With Intermediate-Risk Prostate Cancer Treated With Proton Therapy?
    Takagi, M.
    Demizu, Y.
    Fuwa, N.
    Sulaiman, N. S.
    Jin, D.
    Terashima, K.
    Fujii, O.
    Nagano, F.
    Waki, T.
    Mima, M.
    Niwa, Y.
    Katsui, K.
    Murakami, M.
    Okimoto, T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E263 - E263
  • [47] Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer
    Falchook, Aaron D.
    Basak, Ramsankar
    Mohiuddin, Jahan J.
    Chen, Ronald C.
    CANCER, 2016, 122 (15) : 2341 - 2349
  • [48] Association of age and response to androgen-deprivation therapy with or without radiotherapy for prostate cancer: data from CaPSURE
    Aaronson, David
    Cowan, Janet
    Carroll, Peter
    Konety, Badrinath
    BJU INTERNATIONAL, 2010, 105 (07) : 951 - 955
  • [49] HYPOFRACTIONATED EXTERNAL BEAM RADIOTHERAPY WITHOUT ANDROGEN DEPRIVATION FOR INTERMEDIATE RISK PROSTATE CANCER: PRELIMINARY RESULTS AND TOXICITY ANALYSIS
    Dal Pra, A.
    Faria, S.
    Cury, F.
    David, M.
    Duclos, M.
    Shenouda, G.
    Souhami, L.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S46 - S46
  • [50] Prognostic value of testosterone following androgen deprivation and high-dose radiotherapy in prostate cancer
    Zapatero, A.
    Guerrero, A.
    Maldonado, X.
    Alvarez, A.
    Gonzalez San Segundo, C.
    Cabeza Rodriguez, M. A.
    Martin de Vidales, C.
    Sole, J. M.
    Pedro Olive, A.
    Casas, F.
    Boladeras, A.
    Vazquez de la Torre, M. L.
    Calvo, F. A.
    RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S251 - S252
12345